Arecor Therapeutics plc

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 16:35:22 10/05/2024 BST			5-day change	1st Jan Change
136.5 ^GBX	0.00%		-0.73%	-25.21%

05-09	Arecor Therapeutics collaborates with Medtronic on novel insulin	AN
05-09	Arecor Therapeutics, Medtronic Team Up for Thermostable Insulin Development	MT

Arecor Therapeutics gets "milestone payment" from AT220 sale

November 17, 2023 at 11:46 am

Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it received a "milestone payment" from an unnamed pharmaceutical partner following the first commercial sale of its AT220 product. Chief Executive Officer Sarah Howell says: "The commercialisation of this product in Europe, the first to be launched incorporating our Arestat technology, is a significant milestone for Arecor and further demonstrates the strength of our Arestat platform and the value it can bring to our partners and ultimately patients."

Current stock price: 184.95 pence, up 1.3%

12-month change: down 25%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Arecor Therapeutics plc

Arecor Therapeutics collaborates with Medtronic on novel insulin	05-09	AN
Arecor Therapeutics, Medtronic Team Up for Thermostable Insulin Development	05-09	MT
Arecor and Medtronic Diabetes Collaboration	05-09	CI
Arecor Therapeutics delays publication of 2023 results	05-03	AN
Arecor Therapeutics plc Announces Delay in Publication of the Group's Final Results for the Year Ended 31 December 2023	05-03	CI
Arecor chief financial officer to leave in July after five years	04-23	AN
Arecor Therapeutics CFO to Leave in July	04-23	MT
Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Chief Financial Officer, Effective from July 22, 2024	04-23	CI
Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Company Secretary and as A Board Director, Effective from July 22,2024	04-23	CI
Arecor to develop "holy grail" diabetes treatment with partner TRx	03-12	AN
Arecor Therapeutics plc and Trx Biosciences Limited Announces Research Collaboration for the Formulation Development of an Oral GLP-1 Receptor Agonist Product	03-12	CI
EARNINGS AND TRADING: East Star, Getech strike Kazakhstan JV	02-29	AN
Arecor Therapeutics hails Arestat as 2023 performance "strong"	02-01	AN
Arecor pleased as investee Inhibrx sells therapy to Sanofi	01-23	AN
Patent boosts for DG Innovate and Arecor Therapeutics	01-18	AN
Arecor Therapeutics Gains European Patent for Insulin Product Formulations	01-18	MT
Arecor expands speciality hospital collaboration with partner	01-08	AN
Arecor Therapeutics Expands Formulation Study Collaboration with Pharmaceutical Partner	01-08	MT
Arecor Therapeutics plc Expands Ongoing, Exclusive Formulation Study Collaboration with the Pharmaceutical Division of One of the World's Largest Chemicals Marketing and Pharmaceuticals Companies	01-08	CI
Arecor inks co-development deal with global medical company	12-04	AN
Arecor Therapeutics Signs Exclusive License Option Agreement for Oncology Product	12-04	MT
Arecor Therapeutics plc Announces Co-Development and Exclusive Licence Option Agreement	12-04	CI
Arecor inks Eli Lilly deal; RBG appoints McNair CFO	11-29	AN
Arecor Therapeutics Signs Further Collaboration With Eli Lilly	11-29	MT
Arecor Therapeutics plc Signs Further Collaboration Agreement with Lilly and Company	11-29	CI

Chart Arecor Therapeutics plc

Duration

Period

More charts

Company Profile

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

Sector

Biotechnology & Medical Research

Calendar

12/05/2024 - Q4 2023 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for Arecor Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.365 GBP

Average target price

5.083 GBP

Spread / Average Target

+272.41%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARECOR THERAPEUTICS PLC	-25.21%	52.32M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research